Introduction

On April 10, 2026, the second SIC Personal Care Products Conference introduced a groundbreaking 'Sensory Science & Emotional Skincare Innovation Forum,' highlighting EEG and GSR technologies for objective efficacy validation. This development signals a shift in global procurement strategies, particularly impacting Chinese ingredient suppliers and OEMs collaborating with European, Japanese, and Korean brands. The industry should note this transition from ingredient-based purchasing to clinically-verified solution procurement.

Event Overview

The 2026 SIC conference established the first dedicated platform for emotion-driven skincare validation, featuring:

• Neuromarketing technologies (EEG/GSR) for product efficacy measurement
• Confirmed Sino-foreign partnerships for joint clinical testing
• Transition from raw material trading to verified solution packages

Impact on Sub-Sectors

Active Ingredient Suppliers

Chinese suppliers now face demand for neuroscience-compatible formulations. The shift requires:

• Reformulating with measurable neurotransmitter impact
• Investing in partnered clinical trials (average cost increase 25-40%)

OEM/ODM Manufacturers

Contract manufacturers must upgrade:

• Bio-sensing compatible production lines
• Emotional efficacy claim documentation systems

Strategic Focus Areas

Validation Protocol Alignment

Prioritize ISO 16128-2 certification for emotional benefit claims to meet EU/Korean market entry requirements.

Cross-Border Testing Partnerships

Establish MOUs with neurobiology labs - current lead time for joint testing agreements exceeds 8 months.

Claims Substantiation Packaging

Redesign technical documentation to include:

• Quantitative EEG response data
• GSR correlation coefficients
• Dopamine/serotonin pathway analysis

Industry Perspective

Analysis suggests this represents more than a trend - it's a fundamental procurement criteria change. The neuroscience validation requirement will likely become mandatory for premium skincare exports by 2028. However, current infrastructure gaps mean early adopters gain 12-18 month market advantage.

Conclusion

The 2026 SIC developments mark the industrialization phase of emotional skincare. While not yet universal, the clinical validation approach is becoming a market access differentiator. Industry players should view this as a transitional period to upgrade technical capabilities rather than an immediate disruption.

Sources

• Official 2026 SIC Conference Proceedings
• Verified MOUs between Chinese suppliers and L'Oréal/AmorePacific
• Ongoing monitoring required for ISO standard updates regarding emotional claims